Article
An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors.
EMBO molecular medicine - 1 Feb 2018
Mancini Maicol, Gal Hilah, Gaborit Nadège, Mazzeo Luigi, Romaniello Donatella, Salame Tomer Meir, Lindzen Moshit, Mahlknecht Georg, Enuka Yehoshua, Burton Dominick Ga, Roth Lee, Noronha Ashish, Marrocco Ilaria, Adreka Dan, Altstadter Raya Eilam, Bousquet Emilie, Downward Julian, Maraver Antonio, Krizhanovsky Valery, Yarden Yosef
Abstract excerpt
Epidermal growth factor receptor (EGFR) mutations identify patients with lung cancer who derive benefit from kinase inhibitors. However, most patients eventually develop resistance, primarily due to the T790M second-site mutation. Irreversible inhibitors (e.g., osimertinib/AZD9291) inhibit T790M-EGFR, but several mechanisms, including a third-site mutation, C797S, confer renewed resistance. We previously reported...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.